An interventional study of anti-TNFα in Juvenile Idiopathic Arthritis, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 8 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Arthritis, Juvenile with a site in France — 18 open to participants now, 21 under way, 9 of them phase 3. Arthritis, Juvenile · France.
Among the 71 studies in Arthritis, Juvenile with a site in France, this one is the 23rd largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2017, is one of 13 with no phase, and was the 32nd registered.
367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →18 of the 71 studies in Arthritis, Juvenile with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 2–16
Alfasigma S.p.A. · Sites in France, Belgium, Czechia and 6 more countries
Ages 8–18
Alfasigma S.p.A. · Sites in France, Germany, United Kingdom
Ages 8–18
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, Canada and 5 more countries
Ages 1+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.
This study: 8 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 28
First in 2000; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 76 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 61 across the 50 interventional studies, 274 across the 21 observational. Of the 42 that completed or were terminated, 16 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 71 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 6 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
5 of the studies in Arthritis, Juvenile with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554495Phase 3Alfasigma S.p.A.Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | 2027-06 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
| NCT05927454Institut National de la Santé Et de la Recherche Médicale, FranceAcostill ( RaDiCo Cohort) (RaDiCo Acostill) | 2027-07 |
| NCT07077304Assistance Publique - Hôpitaux de ParisEACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases | 2027-08-31 |
| NCT07634354CHU de ReimsSarcopenia and Juvenile Idiopathic Arthritis | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 71 studies in Arthritis, Juvenile with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
During exercise, energy comes mainly from carbohydrates and lipids. The relative contribution of lipids and glucose as energy substrates to exercise depends on the parameters of the exercise (duration, intensity and level of training) and the physiological conditions of the subject.
Inflammatory diseases such as juvenile idiopathic arthritis (JIA) are treated, for the most severe forms, by biotherapies. These treatments target certain pro-inflammatory cytokines including TNFα. In adults with rheumatoid arthritis several studies have shown that treatment with anti-TNFα increases insulin sensitivity. There is no data on the oxidation of energy substrates during exercise in children and adolescents with AJI, nor on the impact of anti-TNFα treatments on the oxidation of energetic substrates in children.
Investigators hypothesize that, compared to healthy children, children with JIA should exhibit altered oxidation of energy substrates at rest and submaximal physical exercise due to physical deconditioning and inflammation. In addition, those treated with anti-TNFα should have an oxidation profile of energy substrates at exercise different from that of patients not treated with anti-TNFα. Investigators also hypothesize that anti-TNFα treatments modify the contribution of energy chains (aerobic, anaerobic and anaerobic alactic) during the exercise.
Annual evaluation by Lipoxmax test and Wingate anaerobic test (WAnT) during 3 years or until the transition from pediatric to adult care.
For healthy volunteer, only one lipaxmax and Wingate test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
22 patients treated with TNF blockade
Other: anti-TNFα
22 patients without TNF blockade
Other: anti-TNFα
22 matched healthy subjects by pubertal stage and sex
Other: anti-TNFα
Percentage variation of the maximal fat oxidative rate during an exercise between JIA and healthy children. Timing:
Time frame: at day 1 (first test)
Percentage variation of substrates oxidative crossing point during an exercise.
Time frame: at day 1
Description of the contribution of energy systems during supra-maximal physical exercise
Description of the contribution of energy systems during supra-maximal physical exercise in patients with JIA according to JIA subtype, treatments, age, pubertal status, disease status
Time frame: at day 1 (first test)
Ran from Jan 2017 to primary completion in Jun 2019, 29 months.
Of 53 non-industry interventional studies with no phase under Arthritis, Juvenile, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's 29 months is above that.
Counting every sponsor, half of 56 studies reached it within 14 months; a quarter within 8 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Nov 2016 → Jan 2017, primary completion May 2020 → Jun 2019 and completion Sep 2020 → Mar 2021.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →